Tildacerfont
Cat. No.：YN322123
| 产品名称: | Tildacerfont |
| CAS No.: | 1014983-00-6 |
| Chemical Name: | |
| Synonyms: | Tildacerfont;4-(4-chloro-5-(2,5-dimethyl-7-(pentan-3-yl)pyrazolo[1,5-a]pyrimidin-3-yl)thiazol-2-yl)morpholine;3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-7-(1-ethyl-propyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine;7-(1-ethyl-propyl)-3-(4-chloro-2-morpholin-4 |
| 分子量: | 419.97 |
| 分子式: | C20H26ClN5OS |
| SMILES: | ClC1=C(C2C(C([H])([H])[H])=NN3C=2N=C(C([H])([H])[H])C([H])=C3C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])[H])SC(=N1)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Tildacerfont 是一种有效且具有口服活性的促皮质素释放因子 I 型 (CRF1) 受体抑制剂。Tildacerfont 能有效降低促肾上腺皮质激素 (ACTH) 和肾上腺雄激素水平。Tildacerfont 具有良好的安全性。Tildacerfont 可用于研究先天性肾上腺增生症。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
